immune suppressing News
-
Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop Immune-Onc ...
-
Tactiva Therapeutics Co-Founder Kunle Odunsi Elected to National Academy of Medicine
BUFFALO, N.Y., October 16, 2018 — Tactiva Therapeutics, a development stage company targeting a broad range of cancers, announced today that its co-founder Kunle Odunsi, M.D., Ph.D., FRCOG, FACOG, is among the 75 newly elected regular members of the National Academy of Medicine (NAM). Membership of the NAM is considered one of the highest honors in the field of health and medicine and ...
-
Onconova Therapeutics Announces Abstract At The ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory And Improved Safety Profile In Preclinical Models
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of an abstract at the American Society of Clinical Oncology (ASCO) Annual Meeting. Featured in the abstract are preclinical data from in vitro and cell-based assays that demonstrate how ...
-
BriaCell Secures License for a Promising Novel Anti-Cancer Agent
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the ...
-
Journal Publication: CHI3L1 regulates PD-L1 and anti–CHI3L1–PD-1 antibody elicits synergistic antitumor responses.
“Master Pathway” Discovery. Congratulations to our Founder and Scientific Advisory Board Chairman, Dr. Jack A. Elias, on the publication of his breakthrough lung cancer research in the Journal of Clinical Investigation. Referring to the important role played by CHI3L1 in lung cancer metastasis in the accompanying authors note, Dr. Elias says, “We believe we have discovered a ...
-
Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors
Phase 1 multicenter dose-escalation and dose-expansion trial evaluating IO-202 as a monotherapy and in combination with an anti-PD-1 is initiated and expected to enroll 200 patientswith advanced solid tumors This is the second clinical trial for the IO-202 program; its first Phase 1 trial is currently enrolling patients with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia ...
-
New Englanders Reminded that skin cancer is most common, and most preventable cancer in U.S. - sun safety tips for `Don’t Fry Day`: May 25, 2012
With the traditional Memorial Day kick off to summertime activities, EPA is reminding New England citizens and visitors about simple steps to take to protect their skin from too much sun exposure. This year EPA has teamed up with the National Council on Skin Cancer Prevention, Food and Drug Administration and National Park Service to emphasize the dangers of skin cancer. The National Council on ...
-
PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration
OXFORD, UK – 7 April 2021: PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® ...
-
AACR Presentation #1731 : EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy
Our AACR Presentation #1731 is now available. Follow this link to the AACR web site and this link to see our Poster: Abstract Elevated levels of adenosine found in the tumor microenvironment have been highlighted as a potential mechanism contributing to the restricted efficacy of immune checkpoint inhibitors. While the advent of these inhibitors has brought significant benefit to patients with ...
By Exscientia
-
Agilent Technologies and Seoul National University hospital collaborate on biomarker research
Agilent Technologies Inc. (NYSE: A) and Seoul National University Hospital, one of Korea's top medical centers, today announced a strategic collaboration for the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers. "There are gaps in the medical industry that hamper the quality of care we can provide to ...
-
Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-108 in Patients with Advanced Solid Tumors in China
IO-108 is the first LILRB2-targeting antibody administered to Chinese patients Implementation of IO-108 program in China initiates Immune-Onc’s global clinical development plan; Phase 1 trial has completed dose escalation in the U.S. in solid tumor patients Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel ...
-
Skin cancer common but preventable for those who work or play outdoors
The sunny days of spring and summer represent an entirely different dynamic for people in the Midwest. While large numbers of people are heading for camp sites, parks and beaches that flourish throughout our region, it also means that the agriculture community – our farmers and ranchers – are hard at work in the fields and on rangeland. This means that the risk will increase for those ...
-
Jubilant Therapeutics Inc. Doses First Patient in Phase I/II Trial Evaluating JBI-802, dual inhibitor of LSD1 and HDAC6, in patients with advanced solid tumors
JBI-802 is a first-in-class, orally administered, dual equipotent inhibitor of LSD1 & HDAC6 JBI-802 demonstrated synergistic anti-tumor activity in animal models Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced the dosing of the first patient in a ...
-
Immune-Onc Therapeutics Enters into Clinical Collaboration with BeiGene in China
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced it has entered into a clinical trial collaboration and supply agreement with to evaluate Immune-Onc’s first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with ...
-
Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron
IO-108 is being studied as a monotherapy and in combination with select anti-PD-1 antibodies in multiple expansion cohorts of solid tumors Clinical supply agreement with Regeneron accelerates Immune-Onc’s solid tumor clinical development program Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel ...
-
Major Biomedical Catalyst grant win
£1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of ...
-
Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors
Multicenter Phase 1 study to evaluate IO-108 as both monotherapy and in combination with pembrolizumab in China Represents the first LILRB2-targeting antibody with IND clearance in China and the company’s fourth IND globally A Phase 1 trial evaluating IO-108 in patients with advanced solid tumors is currently enrolling in the U.S. Immune-Onc Therapeutics, Inc. ...
-
Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRPα monoclonal antibody ES004, PD-L1/SIRPα bispecific antibody ...
By Elpiscience
-
Immune-Onc Therapeutics Announces Appointment of Christopher Whitmore as Chief Financial Officer and Provides Clinical Progress Update
Company announces completion of Phase 1 dose escalation ahead of schedule for IO-108, a first-in-class antibody targeting LILRB2 (ILT4) Signals of clinical activity observed in multiple tumor types for IO-108 as a single agent and in combination with an anti-PD-1 Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel ...
-
Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022, at 2:00 PM EDT, hosted by Raymond James biotech analysts. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you